索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]许艳,徐威.甲状腺激素与心力衰竭合并房颤的研究进展[J].国际心血管病杂志,2022,02:80-82.
点击复制

甲状腺激素与心力衰竭合并房颤的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年02期
页码:
80-82
栏目:
综述
出版日期:
2022-06-01

文章信息/Info

Title:
-
作者:
许艳; 徐威
甲状腺激素（TH）异常可促进心肌重构，引起心房颤动，导致心力衰竭（心衰） 加重，是心衰预后不良的独立危险因素。心衰时，三碘甲状腺原氨酸水平降低会加重心肌舒 缩功能障碍，使心脏对儿茶酚胺的敏感性和反应性降低，导致心肌内超载，引起心肌纤维化 和炎性反应，使心功能进一步恶化，促使房颤发生。该文介绍TH 参与心衰合并房颤的发生 发展机制的最新进展。
Author(s):
-
关键词:
-
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.02.005
文献标识码:
-
摘要:
甲状腺激素；心力衰竭；心房颤动
Abstract:
-

参考文献/References

[1] 夏平, 杨浩. 心力衰竭合并心房颤动：从基础科学到临床实 践[J]. 国际心血管病杂志, 2016, 43(2):87-89.
[2] Abdel-Moneim A, Gaber AM, Gouda S, et al. Relationship of thyroid dysfunction with cardiovascular diseases: updated review on heart failure progression[J]. Hormones (Athens), 2020, 19(3):301-309.
[3] Carlisle MA, Fudim M, DeVore AD, et al. Heart and atrial fibrillation, like fire and fury[J]. JACC Heart Fail, 2019, 7(6):447-456.
[4] Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?[J]. EMBO Mol Med, 2020, 12(10):e10865.
[5] Cannavo A, Elia A, Liccardo D, et al. Aldosterone and myocardial pathology[J]. Vitam Horm, 2019, 109:387-406.
[6] Martin N, Manoharan K, Davies C, et al. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction[J]. Cochrane Database Syst Rev, 2018, 6(6):CD012721.
[7] Biondi B. The management of thyroid abnormalities in chronic heart failure[J]. Heart Fail Clin, 2019, 15(3):393-398.
[8] Mastorci F, Sabatino L, Vassalle C, et al. Cardioprotection and thyroid hormones in the clinical setting of heart failure[J]. Front Endocrinol (Lausanne), 2019, 10:927.
[9] Modesti PA, Marchetta M, Gamberi T, et al. Reduced expression of thyroid hormone receptors and betaadrenergic receptors in human failing cardiomyocytes[J]. Biochem Pharmacol, 2008, 75(4):900-906.
[10] Laudette M, Formoso K, Lezoualc'h F. GRKs and Epac1 interaction in cardiac remodeling and heart failure[J]. Cells, 2021, 10(1):154.
[11] Shao Q, Cheng HJ, Callahan MF, et al. Overexpression myocardial inducible nitric oxide synthase exacerbates cardiac dysfunction and beta-adrenergic desensitization in experimental hypothyroidism[J]. Int J Cardiol, 2016, 204:229- 241.
[12] Michel LYM, Farah C, Balligand JL. The beta3 adrenergic receptor in healthy and pathological cardiovascular tissues[J]. Cells, 2020, 9(12):2584.
[13] Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation[J]. JACC Clin Electrophysiol, 2017, 3(5):425-435.
[14] Zeng B, Liu L, Liao X, et al. Thyroid hormone protects cardiomyocytes from H2O2-induced oxidative stress via the PI3K-AKT signaling pathway[J]. Exp Cell Res, 2019, 380(2):205-215.
[15] Vassalle C. New biomarkers and traditional cardiovascular risk scores: any crystal ball for current effective advice and future exact prediction?[J]. Clin Chem Lab Med, 2018, 56(11):1803- 1805.
[16] Mancini A, Vergani E, Bruno C, et al. Oxidative stress as a possible mechanism underlying multi-hormonal deficiency in chronic heart failure[J]. Eur Rev Med Pharmacol Sci, 2018, 22(12):3936-3961.
[17] Marín-García J. Thyroid hormone and myocardial mitochondrial biogenesis[J]. Vascul Pharmacol, 2010, 52(3/4):120-130.
[18] Sinha RA, Singh BK, Zhou J, et al. Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROSAMPK- ULK1 signaling[J]. Autophagy, 2015, 11(8):1341- 1357.
[19] Lanni A, Moreno M, Goglia F. Mitochondrial actions of thyroid hormone[J]. Compr Physiol, 2016, 6(4):1591-1607.
[20] Khakisahneh S, Zhang XY, Nouri Z,et al.Thyroid hormones mediate metabolic rate and oxidative, anti-oxidative balance at difffferent temperatures in Mongolian gerbils (Meriones unguiculatus)[J]. Comp Biochem Physiol C Toxicol Pharmacol, 2019, 216:101-109.
[21] Al-Khaldi A, Sultan S. The expression of sirtuins, superoxide dismutase, and lipid peroxidation status in peripheral blood from patients with diabetes and hypothyroidism[J]. BMC Endocr Disord, 2019, 19(1):19.
[22] Harada M, Nattel S. Implications of inflammation and fibrosis in atrial fibrillation pathophysiology[J]. Card Electrophysiol Clin, 2021, 13(1):25-35.
[23] Burger D, Gagnon A, Lochnan HA, et al. Thyroid-stimulating hormone acutely increases levels of circulating pro-coagulant microparticles[J]. Clin Endocrinol (Oxf), 2015, 83(2):285-287.
[24] Zhang YJ, Zhao W, Zhu MY, et al. Thyroid-stimulating hormone induces the secretion of tumor necrosis factor-α from 3T3-L1 adipocytes via a protein kinase a-dependent pathway[J]. Exp Clin Endocrinol Diabetes, 2013, 121(8):488- 493.
[25] Mancini A, Di Segni C, Raimondo S, et al. Thyroid hormones, oxidative stress, and inflammation[J]. Mediators Inflamm, 2016:6757154.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81400294）
作者单位：150081 哈尔滨医科大学附属第二医院心内科
通信作者：徐威, E-mail: vivie1977@163.com
更新日期/Last Update: 2022-06-01